Rongtai Health: No downward revisions to the “Rongtai Bonds” conversion price

Shanghai Rongtai Health Technology Co., Ltd. announced that as of May 16, 2024, the company's stock price had experienced a situation where the closing price for at least 15 out of 30 consecutive trading days was less than 80% of the current share conversion price, triggering a downward revision of the “Rongtai Bonds” conversion price. After deliberation and approval at the 16th meeting of the fourth board of directors held on May 16, 2024, the board of directors of the company decided not to revise the “Rongtai Bonds” conversion price downward this time, and within the next six months (that is, from May 17, 2024 to November 16, 2024), if the “Rongtai Bonds Transfer” share conversion price is triggered again

Zhitong FinanceMay 16 18:10

Rongtai Health: “Rongtai Bonds Transfer” is expected to trigger downward correction conditions for share conversion prices

Shanghai Rongtai Health Technology Co., Ltd. announced that from April 23, 2024 to May 9, 2024, the closing price of the company's stock was lower than 80% of the current conversion price (25.33 yuan/share) for 10 trading days, which is expected to trigger downward revision conditions for the share conversion price.

Zhitong FinanceMay 9 21:48

Rongtai Health (603579): Profitability significantly improved in 2024Q1, regional structure optimization

Event: On April 25, 2024, Rongtai Health released its 2024 quarterly report. 2024Q1 revenue/net profit attributable to mother/net profit excluding non-return to mother were 4.01/0.61 billion yuan, respectively, year-on-year share

方正證券Apr 27 00:00

Rongtai Health (603579): Export revenue was slightly pressured, profit improved sharply, exceeding expectations

Report guide: Rongtai Health released its 2024 quarterly report. The company achieved revenue of 401 million yuan in 24Q1, +3.86% year over year; net profit to mother of 62.74 million yuan, +67.31% year over year; net profit after deduction 6

浙商證券Apr 26 00:00

Capital Securities released a research report on April 24 stating that it gave Rongtai Health (603579.SH) a purchase rating. The main reasons for the rating include: 1) annual revenue declined under pressure, and the revenue growth rate rose at an inflect

Capital Securities released a research report on April 24 stating that it gave Rongtai Health (603579.SH) a purchase rating. The main reasons for the rating include: 1) annual revenue declined under pressure, and the revenue growth rate rose at an inflection point in Q4; 2) falling raw material prices & optimization of product and customer structures, and improvement in profit levels. (Mainichi Keizai Shimbun)

Zhitong FinanceApr 24 08:39

Rongtai Health (603579) Company Brief Review Report: Q4 Revenue Growth Inflection Point Upward, Profitability Continues to Repair

Incident: The company released its 2023 annual report, achieving full-year revenue of 1,855 million yuan, -7.47%; net profit to mother of 203 million yuan, +23.43% year-on-year; net profit after deducting non-return to mother of 186 million, +47 year-on-year

首創證券Apr 23 00:00